M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 7.1 PLN
Market Cap: zł146.3m

Relative Value

The Relative Value of one MOC stock under the Base Case scenario is 3.5 PLN. Compared to the current market price of 7.1 PLN, Molecure SA is Overvalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOC Relative Value
Base Case
3.5 PLN
Overvaluation 51%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Multiples Across Competitors

MOC Competitors Multiples
Molecure SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Molecure SA
WSE:MOC
146.3m PLN 28.6 -6 -5.5 -5.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.6 39.3
US
Johnson & Johnson
NYSE:JNJ
530.8B USD 5.7 19.9 13.9 17
CH
Roche Holding AG
SIX:ROG
279.4B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
214.1B GBP 5 30.8 20 29.3
CH
Novartis AG
SIX:NOVN
224.2B CHF 5 19.6 15.7 20.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17 11.8 13.7
US
Merck & Co Inc
NYSE:MRK
267.6B USD 4.2 14 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.1B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
96.7B EUR 1.5 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
PL
M
Molecure SA
WSE:MOC
Average P/E: 23
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.9
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
38%
0.8
CH
Novartis AG
SIX:NOVN
19.6
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
17
2%
8.5
US
Merck & Co Inc
NYSE:MRK
14
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
7
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBITDA: 47.9
Negative Multiple: -5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.6
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.9
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20
10%
2
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
1%
11.8
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBIT: 102.8
Negative Multiple: -5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.3
23%
1.3
CH
Novartis AG
SIX:NOVN
20.3
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4